Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 34 of 88 · 4213 articles
Barrier dysfunction is central to IBD pathogenesis; a compound that restores tight junctions and reduces permeability in preclinical models could eventually lead to new therapies that protect the gut lining and reduce...
Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.
Many people with IBD also have overweight or obesity; GLP-1 receptor agonists are being used for weight loss and may affect inflammation and IBD outcomes. This review summarizes current evidence on safety, effectiveness,...
The microbiome is connected to IBD through effects on immune regulation and barrier function; advances in understanding could inform future microbiome-directed therapies that matter to people with IBD.
A new single-cell analysis tool may help researchers and clinicians studying IBD (here shown for ulcerative colitis) to detect and interpret changes in cell–cell signaling that accompany disease or treatment response.
Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.
People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...
This study reports a non-invasive fluorescence probe that detects a reactive nitrogen species (peroxynitrite) linked to intestinal inflammation and shows signal changes in cells, animal models, and mouse feces — a...
A potential link between ultra-processed food intake and Crohn’s relapse could influence dietary conversations for people in remission, but the current evidence is weak and not definitive.
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...
A drug (flucytosine) caused colitis that looked like an ulcerative colitis flare. Mistaking medication-induced colitis for IBD activity could lead to unnecessary changes in immunosuppressive treatment.
Many patients and clinicians seek safer, non-immunosuppressive options for Crohn’s disease. This randomized trial found LDN did not induce endoscopic or clinical remission, though it may reduce fatigue—information that...
Genetic evidence for causal links between other diseases (for example asthma or multiple sclerosis) and IBD can help researchers prioritize biological pathways and potential therapeutic targets, and may explain why some...
A naturally occurring pigment (C3G) improved inflammation and barrier markers in a mouse colitis model, which could be of interest to people exploring nutrition-related ways to support gut health.
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. The original article is from Inflammatory Bowel...
This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from fox2detroit.com.
Local foundation stories can point people with Crohn’s or colitis toward community support, volunteering opportunities, and local resources. They may help viewers find ways to get involved or access services nearby.
This study describes a new microbiome-engineering approach that reduced inflammation in mouse colitis models by sequestering cysteine and altering T cell behavior. If followed up, it could point to novel future therapies...
Because PG is linked to IBD and can be triggered by surgery, a perioperative immunosuppressive approach reported here may be relevant to patients with IBD who have had prior PG or are planning reconstructive surgery.
Fibrosis and stricture formation are important complications in Crohn’s disease; a biopsy-based, quantitative way to measure collagen architecture could help research into fibrotic disease mechanisms and eventually...
The study suggests that a simple, multidomain functional measure (intrinsic capacity) is linked to later IBD risk and that combining it with genetic risk may better identify people at higher risk—especially for Crohn’s...
For people with ulcerative colitis needing restorative surgery, the choice between robotic and laparoscopic IPAA may affect short-term surgical outcomes and recovery.
PFAS exposure is widespread; if PFNA worsens intestinal inflammation through a defined immune pathway, it could help explain environmental contributions to IBD flares and point to new research targets for mitigation.
This preclinical study suggests a heat‑killed form of Lactobacillus acidophilus LA‑5 reduced inflammation, oxidative stress, and markers of regulated cell death in a mouse model of ulcerative colitis — with effects...
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Patients who lose response to standard upadacitinib dosing may have a practical option—dose re‑escalation—that could improve symptoms and reduce steroid needs according to a small retrospective cohort summarized here.
FUT2-dependent intestinal fucosylation helps shape which gut microbes thrive and how the mucosa resists pathogens. For people with IBD, differences in FUT2 function and altered fucosylation may contribute to microbiome...
This study provides preclinical evidence that an anthocyanin (cyanidin-3-O-glucoside) can reduce inflammation and preserve the intestinal barrier in a mouse colitis model, highlighting a possible dietary mechanism...
If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the...
Macrophage behavior and metabolic reprogramming help drive inflammation or repair in ulcerative colitis, so understanding these processes could point to new therapies. The review links lab methods and ongoing clinical...
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
This study describes a novel colon-targeted microgel delivery system carrying an anti-inflammatory natural compound that, in a mouse model, reduced colitis signs and altered gut bacteria — a potential new strategy for...
This atlas maps when and where regenerative gene programs turn on in the intestine and highlights molecular features (like interferon responses and hypertranscription) that overlap with human Crohn’s disease, so it could...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Complications. The original article is from Cureus.
Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.
The study shows malnutrition is common in Crohn’s disease and much more likely during active inflammation, highlighting the need for routine nutritional screening and more than one type of assessment.
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
Persistent fatigue is a common disabling symptom in IBD even during remission; a structured adapted physical activity program could offer a non-drug way to improve daily functioning if the trial shows benefit.
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is...
Researchers can use these human tissue slice cultures to study inflammation and test drugs on a patient’s own biopsy tissue, which could eventually help explain treatment response or resistance in IBD and related...
A parasitic infection (Ascaris) can closely imitate Crohn’s disease or microscopic colitis and lead to harmful misdiagnosis and unnecessary immunosuppression. Patients in or from helminth-endemic areas with new IBD-like...
The study links a common dietary fiber (green banana resistant starch) to microbiota changes and production of propionate that protect the colonic barrier and reduce inflammation in a mouse model of ulcerative colitis.
This study proposes specific plant compounds and molecular pathways that could be relevant to ulcerative colitis, which may guide future lab research and drug-discovery efforts. For people with UC, it points to...
The study suggests molecular targets and pathways through which a traditional herbal formula might influence UC biology, offering testable hypotheses for future lab and clinical research.
